PBYI - Puma Bio: Still Worthy Of Consideration After Earnings Surprise

• Puma Biotechnology recently reported its Q4 and full-year 2021 earnings that revealed a solid beat on EPS and revenue. The company reported $55.4M in total revenue for Q4 of 2021.
• NERLYNX net revenue came in at $51M for Q4, which was up from $43.4M in Q3 and $50M in Q4 of 2020. This triggered a positive move in PBYI.
• I believe Puma’s earnings should encourage investors to keep a close eye on PBYI for a potential turnaround in the coming years.
• It looks as if Puma has the prospects for a turnaround in the coming years, which could provide numerous trading opportunities.
• PBYI's charts look atrocious, so I am going to wait for a definitive break in the downtrend line and a reversal pattern on the daily chart before I click the buy button.

For further details see: